Vaccines, Adjuvants, and Delivery Systems

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):

Share By

Vaccines, Adjuvants, and Delivery Systems Publisher

Keshavarzfathi M^{1, 2, 3} ; Rezaei N^{3, 4, 5}

Source: Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives Published:2018

Abstract

Vaccines have been used as a preventive modality against infectious disease for a long time. The application of vaccines to treat the diseases, which have interactions with the immune system, have revealed a new concept of immunotherapy, known as therapeutic vaccines. Many efforts have been made to utilize this modality in the most efficient way. To optimize the current vaccines, understanding the determinants such as selection of the appropriate antigens, combination of effective adjuvants, application of a delivery system, and administration through the proper route are necessary. In this chapter, we will discuss the mentioned determinants to prepare the background for extending the knowledge of vaccinology. © 2019 Nima Rezaei and Mahsa Keshavarz-Fathi Published by Elsevier Ltd All rights reserved.

Related Docs

View other Related Docs

1. Vaccines, Adjuvants, and Delivery Systems, Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives (2019)

2. Toll-Like Receptors (Tlrs) in Cancer; With an Extensive Focus on Tlr Agonists and Antagonists, IUBMB Life (2021)

3. Concluding Remarks and Future Perspectives on Therapeutic Cancer Vaccines, Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives (2019)

Experts (# of related papers)

View all Related Experts

Nima Rezaei (13)

Ziba Veisi Malekshahi (1)

Other Related Docs

4. Concluding Remarks and Future Perspectives on Therapeutic Cancer Vaccines, Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives (2018)

5. Immunogenicity of Different Types of Adjuvants and Nano-Adjuvants in Veterinary Vaccines: A Comprehensive Review, Vaccines (2023)

6. Conjugated Nanoliposome With the Her2/ Neu-Derived Peptide Gp2 As an Effective Vaccine Against Breast Cancer in Mice Xenograft Model, PLoS ONE (2017)

7. Cancer Immunoprevention: Current Status and Future Directions, Archivum Immunologiae et Therapiae Experimentalis (2021)

8. Genetic Vaccine for Cancer, Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives (2019)

9. Killed Whole-Cell Staphylococcus Aureus Formulation in Montanide Isa266 and Alum Adjuvants: Different Vaccine Formulations Varied in the Vaccine’S Potency and Efficacy, Immunologic Research (2025)

10. Self-Assembling Peptide Epitopes As Novel Platform for Anticancer Vaccination, Molecular Pharmaceutics (2017)

11. Polymeric Nanoparticles for Dna Vaccine-Based Cancer Immunotherapy: A Review, Biotechnology Letters (2023)

12. Peptide and Protein Vaccines for Cancer, Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives (2019)

13. Cancer Immunology, Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives (2018)

14. Cancer Immunology, Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives (2019)

15. Peptide and Protein Vaccines for Cancer, Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives (2018)

16. Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives, Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives (2018)

17. Obstacles in the Development of Therapeutic Cancer Vaccines, Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives (2018)

18. D D a Strategies to Designing Chimeric Recombinant Vaccines, Journal of Applied Biotechnology Reports (2021)

19. Immune Cell Vaccine For Cancer, Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives (2019)

20. The Role of Toll-Like Receptors in Neuropsychiatric Disorders: Immunopathology, Treatment, and Management, Medicinal Research Reviews (2024)

Style	Citing Format
MLA	Keshavarzfathi M, Rezaei N. "Vaccines, Adjuvants, and Delivery Systems." Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives, vol. , no. , 2018, pp. 45-59.
APA	Keshavarzfathi M, Rezaei N (2018). Vaccines, Adjuvants, and Delivery Systems. Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives, (), 45-59.
Chicago	Keshavarzfathi M, Rezaei N. "Vaccines, Adjuvants, and Delivery Systems." Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives , no. (2018): 45-59.
Harvard	Keshavarzfathi M, Rezaei N (2018) 'Vaccines, Adjuvants, and Delivery Systems', Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives, (), pp. 45-59.
Vancouver	Keshavarzfathi M, Rezaei N. Vaccines, Adjuvants, and Delivery Systems. Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives. 2018;():45-59.
BibTex	@article{ author = {Keshavarzfathi M and Rezaei N}, title = {Vaccines, Adjuvants, and Delivery Systems}, journal = {Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives}, volume = {}, number = {}, pages = {45-59}, year = {2018} }
RIS	TY - JOUR AU - Keshavarzfathi M AU - Rezaei N TI - Vaccines, Adjuvants, and Delivery Systems JO - Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives VL - IS - SP - 45 EP - 59 PY - 2018 ER -

Science Communicator Platform

Authors

Abstract